We've found
6,982
archived clinical trials in
Endocrine
We've found
6,982
archived clinical trials in
Endocrine
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
Updated: 12/31/1969
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape).
Status: Enrolling
Updated: 12/31/1969
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
Updated: 12/31/1969
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape).
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
Updated: 12/31/1969
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape).
Status: Enrolling
Updated: 12/31/1969
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
Updated: 12/31/1969
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape).
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Exercise Study of Function and Pathology for Women With X-linked Adrenoleukodystrophy
Updated: 12/31/1969
Exercise Study of Function and Pathology for Women With X-ALD
Status: Enrolling
Updated: 12/31/1969
Exercise Study of Function and Pathology for Women With X-linked Adrenoleukodystrophy
Updated: 12/31/1969
Exercise Study of Function and Pathology for Women With X-ALD
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
Updated: 12/31/1969
A Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 12/31/1969
Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
Updated: 12/31/1969
A Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
Updated: 12/31/1969
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
Status: Enrolling
Updated: 12/31/1969
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
Updated: 12/31/1969
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
Updated: 12/31/1969
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
Status: Enrolling
Updated: 12/31/1969
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
Updated: 12/31/1969
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
EPI-743 for Metabolism or Mitochondrial Disorders
Updated: 12/31/1969
Therapeutic Trial of EPI -743 In Patients With Disorders of Energy Utilization or Oxidation-Reduction
Status: Enrolling
Updated: 12/31/1969
EPI-743 for Metabolism or Mitochondrial Disorders
Updated: 12/31/1969
Therapeutic Trial of EPI -743 In Patients With Disorders of Energy Utilization or Oxidation-Reduction
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome
Updated: 12/31/1969
Effects of Pharmacological Reversal of Hyperuricemia on Features of the Metabolic Syndrome
Status: Enrolling
Updated: 12/31/1969
Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome
Updated: 12/31/1969
Effects of Pharmacological Reversal of Hyperuricemia on Features of the Metabolic Syndrome
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cross-Sectional Iloperidone IVGTT
Updated: 12/31/1969
Cross-sectional Study to Compare Glucose and Lipid Metabolism in SMI Subjects Treated With Either Fanapt (Iloperidone), Zyprexa (Olanzapine), or Risperdal (Risperidone)
Status: Enrolling
Updated: 12/31/1969
Cross-Sectional Iloperidone IVGTT
Updated: 12/31/1969
Cross-sectional Study to Compare Glucose and Lipid Metabolism in SMI Subjects Treated With Either Fanapt (Iloperidone), Zyprexa (Olanzapine), or Risperdal (Risperidone)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin
Updated: 12/31/1969
Androgen-mediated Pathways in the Regulation of Insulin Sensitivity in Men
Status: Enrolling
Updated: 12/31/1969
T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin
Updated: 12/31/1969
Androgen-mediated Pathways in the Regulation of Insulin Sensitivity in Men
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
Updated: 12/31/1969
Pharmacodynamic Study of Vemurafenib in the Neoadjuvant Setting in Patients With Locally Advanced Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
Updated: 12/31/1969
Pharmacodynamic Study of Vemurafenib in the Neoadjuvant Setting in Patients With Locally Advanced Thyroid Cancer
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Updated: 12/31/1969
A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Resveratrol and the Metabolic Syndrome
Updated: 12/31/1969
The Effects of Trans-Resveratrol (RSV) on Insulin Resistance, Inflammation, and the Metabolic Syndrome: A Placebo Controlled, Double-Blind Study.
Status: Enrolling
Updated: 12/31/1969
Resveratrol and the Metabolic Syndrome
Updated: 12/31/1969
The Effects of Trans-Resveratrol (RSV) on Insulin Resistance, Inflammation, and the Metabolic Syndrome: A Placebo Controlled, Double-Blind Study.
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
Updated: 12/31/1969
Targeting Autophagy for the Treatment of TSC and LAM: a Phase I Trial of Hydroxychloroquine and Sirolimus
Status: Enrolling
Updated: 12/31/1969
Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
Updated: 12/31/1969
Targeting Autophagy for the Treatment of TSC and LAM: a Phase I Trial of Hydroxychloroquine and Sirolimus
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
Updated: 12/31/1969
Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI and Severe Juvenile Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
Updated: 12/31/1969
Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI and Severe Juvenile Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
Updated: 12/31/1969
Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI and Severe Juvenile Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
Updated: 12/31/1969
Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI and Severe Juvenile Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
Updated: 12/31/1969
Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI and Severe Juvenile Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
Updated: 12/31/1969
Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI and Severe Juvenile Dermatomyositis
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Updated: 12/31/1969
A Retrospective, Non-interventional Epidemiologic Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Status: Enrolling
Updated: 12/31/1969
A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Updated: 12/31/1969
A Retrospective, Non-interventional Epidemiologic Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Updated: 12/31/1969
A Retrospective, Non-interventional Epidemiologic Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Status: Enrolling
Updated: 12/31/1969
A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Updated: 12/31/1969
A Retrospective, Non-interventional Epidemiologic Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Updated: 12/31/1969
A Retrospective, Non-interventional Epidemiologic Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Status: Enrolling
Updated: 12/31/1969
A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Updated: 12/31/1969
A Retrospective, Non-interventional Epidemiologic Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Updated: 12/31/1969
A Retrospective, Non-interventional Epidemiologic Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Status: Enrolling
Updated: 12/31/1969
A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Updated: 12/31/1969
A Retrospective, Non-interventional Epidemiologic Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Updated: 12/31/1969
A Retrospective, Non-interventional Epidemiologic Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Status: Enrolling
Updated: 12/31/1969
A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Updated: 12/31/1969
A Retrospective, Non-interventional Epidemiologic Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Updated: 12/31/1969
A Retrospective, Non-interventional Epidemiologic Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Status: Enrolling
Updated: 12/31/1969
A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Updated: 12/31/1969
A Retrospective, Non-interventional Epidemiologic Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
The Acute and Chronic Effects of Fruit Polyphenols on Chronic Disease (PPF)
Updated: 12/31/1969
A Randomized Placebo Controlled Trial to Test the Acute and Chronic Effects of Fruit Polyphenols on Postprandial Indices of Chronic Disease (PPF)
Status: Enrolling
Updated: 12/31/1969
The Acute and Chronic Effects of Fruit Polyphenols on Chronic Disease (PPF)
Updated: 12/31/1969
A Randomized Placebo Controlled Trial to Test the Acute and Chronic Effects of Fruit Polyphenols on Postprandial Indices of Chronic Disease (PPF)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease
Updated: 12/31/1969
The Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease (in the Grant Entitled: Endothelial Dysfunction in the Pathogenesis of Sickle Cell Nephropathy)
Status: Enrolling
Updated: 12/31/1969
Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease
Updated: 12/31/1969
The Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease (in the Grant Entitled: Endothelial Dysfunction in the Pathogenesis of Sickle Cell Nephropathy)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Insulin Resistance and Cognitive Dysfunction in Obese Adolescents: Pilot Study
Updated: 12/31/1969
Insulin Resistance and Cognitive Dysfunction in Obese Adolescents: Pilot Study
Status: Enrolling
Updated: 12/31/1969
Insulin Resistance and Cognitive Dysfunction in Obese Adolescents: Pilot Study
Updated: 12/31/1969
Insulin Resistance and Cognitive Dysfunction in Obese Adolescents: Pilot Study
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Adipose Tissue and Polycystic Ovary Syndrome (PCOS)(EIFFEL)
Updated: 12/31/1969
Adipose Tissue Angiogenesis in Polycystic Ovary Syndrome (PCOS)
Status: Enrolling
Updated: 12/31/1969
Adipose Tissue and Polycystic Ovary Syndrome (PCOS)(EIFFEL)
Updated: 12/31/1969
Adipose Tissue Angiogenesis in Polycystic Ovary Syndrome (PCOS)
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials
Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women
Updated: 12/31/1969
Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women
Status: Enrolling
Updated: 12/31/1969
Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women
Updated: 12/31/1969
Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women
Status: Enrolling
Updated: 12/31/1969
Click here to add this to my saved trials